Earnings ·
BioNTech SE filed a Form 6-K on August 4, 2026, reporting unaudited financial results for the three and six months…
BNTXBioNTech SE
BioNTech SE filed a Form 6-K on August 4, 2026, reporting unaudited financial results for the three and six months ended June 30, 2026. The company reported revenues of €105.6 million for the quarter, down from €260.8 million in the prior year period. For the first half of 2026, revenues totaled €223.7 million compared to €443.6 million in the same period of 2025. The company incurred a net loss of €820.8 million for the quarter and €1,352.7 million for the six-month period. Cash and cash equivalents stood at €9,741.0 million as of June 30, 2026. BioNTech SE operates in the biotechnology industry, focusing on next-generation immunotherapies and mRNA-based medicines for cancer and infectious diseases.